CLINICAL_TRIALS
trial_result
· 2019-02-12
Clinical Trial Update: Phase 1 Study of Quizartinib [Phase 1]
Summary
The document describes the completion of a Phase 1 trial of quizartinib in relapsed or refractory acute myeloid leukemia.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Relapsed AML, Refractory AML | Phase 1 | Status: COMPLETED